Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324465 | 0.90 | NOD1 (0.57) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL25715312 | 0.90 | NOD1 (0.57) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL21955523 | 0.90 | NOD1 (0.57) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL21282066 | 0.90 | NOD1 (0.57) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL24796368 | 0.88 | NOD1 (0.73) | NOD1SLC6A5KMT2A | |
| SCHEMBL22586479 | 0.88 | NOD1 (0.60) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL27403804 | 0.88 | NOD1 (0.60) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL27403810 | 0.88 | NOD1 (0.60) | NOD1SLC6A5KMT2AGNPAT | |
| SCHEMBL19273454 | 0.88 | NOD1 (0.73) | NOD1SLC6A5KMT2A | |
| SCHEMBL29324486 | 0.87 | NOD1 (0.76) | NOD1SLC6A5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NOD1 1373/4885SLC6A5 2437/4885KMT2A 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.